Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
The Candel Therapeutics, Inc. (CADL) news page on Stock Titan aggregates company-issued updates, press releases, and related coverage focused on its multimodal viral immunotherapy programs in oncology. Candel describes itself as a clinical-stage biopharmaceutical company developing off-the-shelf biological immunotherapies based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, with lead candidates CAN-2409 and CAN-3110 in solid tumors.
Visitors to this page can follow announcements about clinical trial progress, including pivotal and phase 2 studies of CAN-2409 in intermediate-to-high-risk localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC), as well as phase 1b data for CAN-3110 in recurrent high-grade glioma. Candel’s releases also highlight regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug Designation granted by the U.S. Food and Drug Administration for specific indications.
News items frequently cover scientific presentations at major conferences, including ASTRO, ASCO, and the Society for Immunotherapy of Cancer (SITC), where Candel discusses subgroup analyses, biomarker findings, and multi-omics data related to its viral immunotherapy approach. Additional updates describe financing transactions, such as equity offerings and a term loan facility, as well as corporate developments like research advisory board appointments and investor conference participation.
By reviewing the CADL news feed, investors and researchers can see how Candel communicates the evolution of its CAN-2409 and CAN-3110 programs, the role of the enLIGHTEN™ Discovery Platform, and key milestones disclosed in its own press releases and referenced in SEC filings. Bookmark this page to access a centralized view of Candel’s publicly released information on its oncology-focused pipeline and corporate activities.
Candel Therapeutics, a late-stage biopharmaceutical firm, announced that its CEO Paul Peter Tak and investigator E. Antonio Chiocca will present data on oncolytic viral immunotherapies for glioblastoma at two conferences on Oct. 6 and 27, 2021. The presentations will cover novel therapies CAN-2409 and CAN-3110, focusing on their mechanisms and clinical trial results. CAN-2409 targets a wide range of solid tumors while CAN-3110 is under investigation for recurrent high-grade glioma. More details are available on Candel's website.
Candel Therapeutics, Inc. (Nasdaq: CADL) announces key clinical presentations at two upcoming medical conferences focusing on prostate and brain cancer. Dr. Scott E. Eggener will present safety data from the phase 2 trial of CAN-2409 for localized prostate cancer at the AdMeTech Foundation’s Global Summit on September 25, 2021. Concurrently, Dr. E. Antonio Chiocca will share clinical findings from the phase 1 trial of CAN-3110 targeting recurrent high-grade glioma at the European Association of Neuro-Oncology meeting on September 25-26, 2021. Both presentations will highlight advancements in their respective cancer programs.
Candel Therapeutics (Nasdaq: CADL) reported its Q2 2021 financial results, revealing a net loss of $17.1 million, up from $2.9 million in Q2 2020. The company's cash and equivalents decreased to $24.3 million, down from $35.1 million at the end of 2020. Candel recently completed its IPO, raising $71.5 million to fund its ongoing research, with plans to extend its cash runway to Q2 2023. Significant clinical advancements include the FDA's Fast Track designation for CAN-2409 and successful enrollment in multiple clinical trials.
Candel Therapeutics, Inc. (Nasdaq: CADL) has completed patient enrollment in its pivotal phase 3 study of CAN-2409 for intermediate-high risk localized prostate cancer. This randomized, placebo-controlled trial evaluates CAN-2409 combined with valacyclovir alongside standard external beam radiation therapy. The primary focus is on disease-free survival and aims to provide an innovative treatment option to improve patient outcomes while minimizing the side effects of long-term androgen deprivation therapy. Results are anticipated in 2024, potentially influencing future treatment protocols.
Candel Therapeutics announced the closing of an additional 887,994 shares of common stock at $8.00 each, generating approximately $7.1 million. This follows their earlier initial public offering of 9,000,000 shares, raising total gross proceeds to about $79.1 million. Jefferies, Credit Suisse, BMO Capital Markets, and UBS Investment Bank served as joint book-running managers. Candel is focused on developing oncolytic viral immunotherapies aimed at cancer treatment through engineered viruses that induce immunogenic cell death.
Candel Therapeutics has announced the pricing of its initial public offering (IPO) of 9,000,000 shares at $8.00 per share, aiming for gross proceeds of $72 million. Trading on the Nasdaq Global Market under the ticker CADL is set to commence on July 27, 2021, with the offering expected to close on July 29, 2021. The underwriters also hold a 30-day option to acquire an additional 1,350,000 shares. Candel focuses on developing oncolytic viral immunotherapies to treat cancer.